Overview
- AWS introduced the platform Tuesday at its Life Sciences Symposium in New York with early users including Bayer, the Broad Institute, and Voyager Therapeutics.
- The app lets researchers run no‑code workflows on a library of biological foundation models, large AI systems trained on biological data, guided by an AI agent.
- Shortlisted molecules flow to integrated partners such as Twist Bioscience and Ginkgo Bioworks for synthesis and tests, and results feed back to guide the next design round.
- In a project with Memorial Sloan Kettering, the system generated about 300,000 antibody designs and sent 100,000 to Twist for testing, shrinking months of work to weeks.
- A free trial offers five experimental units, and AWS is also unveiling with BCG and Merck an AI tool to improve clinical trial site selection.